Welcome to Markets Desk, your midday read on the stories moving markets.
China is making its most serious move yet to challenge dollar dominance in global trade. Beijing's cross-border digital payments platform, backed by the central banks of Hong Kong, Thailand, the UAE, and Saudi Arabia, signals a coordinated effort to route international settlements outside the dollar system. The geopolitical and currency implications here are significant and long-term.
Turning to deal flow, Medtronic has closed its five hundred fifty million dollar acquisition of Scientia Vascular, with additional milestone payments potentially on the table. The deal bolsters Medtronic's neurovascular portfolio at a time when the company is actively reshaping its business mix. Investors will be watching whether the integration drives margin contribution in the near term.
And in biotech, Upstream Bio delivered encouraging Phase two data on Verekitug for chronic rhinosinusitis with nasal polyps. The VIBRANT trial's responder analyses showed a significant majority of patients experiencing clinically meaningful improvements, a threshold that matters enormously when regulators and payers eventually assess the drug's commercial case. Shares of UPB will be worth watching on the back of this readout.
That's the tape. Markets Desk, signing off the floor.
